Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
Quince Therapeutics (Nasdaq: QNCX), a late-stage biotechnology company focusing on rare disease treatments through patient biology, has announced its upcoming participation in the Jones Healthcare and Technology Innovation Conference.
The company's CEO and CMO, Dr. Dirk Thye, will deliver a presentation on Wednesday, April 9, 2025. Investors and interested parties can access a replay of the presentation through the Events section of Quince's Investor Relations website at ir.quincetx.com.
Quince Therapeutics (Nasdaq: QNCX), un'azienda biotecnologica in fase avanzata che si concentra sui trattamenti per malattie rare attraverso la biologia dei pazienti, ha annunciato la sua prossima partecipazione alla Jones Healthcare and Technology Innovation Conference.
Il CEO e CMO dell'azienda, Dr. Dirk Thye, terrà una presentazione mercoledì 9 aprile 2025. Gli investitori e le parti interessate possono accedere a una registrazione della presentazione tramite la sezione Eventi del sito web delle Relazioni con gli Investitori di Quince all'indirizzo ir.quincetx.com.
Quince Therapeutics (Nasdaq: QNCX), una empresa biotecnológica en etapa avanzada centrada en tratamientos para enfermedades raras a través de la biología del paciente, ha anunciado su próxima participación en la Jones Healthcare and Technology Innovation Conference.
El CEO y CMO de la empresa, Dr. Dirk Thye, realizará una presentación el miércoles 9 de abril de 2025. Los inversores y partes interesadas pueden acceder a una repetición de la presentación a través de la sección de Eventos en el sitio web de Relaciones con Inversores de Quince en ir.quincetx.com.
Quince Therapeutics (Nasdaq: QNCX), 환자 생물학을 통해 희귀 질환 치료에 집중하는 후기 단계 생명공학 회사가 Jones Healthcare and Technology Innovation Conference에 참여할 예정이라고 발표했습니다.
회사의 CEO이자 CMO인 Dr. Dirk Thye는 2025년 4월 9일 수요일에 발표를 진행할 예정입니다. 투자자와 관심 있는 분들은 Quince의 투자자 관계 웹사이트 ir.quincetx.com의 이벤트 섹션을 통해 발표 재생을 이용할 수 있습니다.
Quince Therapeutics (Nasdaq: QNCX), une entreprise de biotechnologie en phase avancée axée sur les traitements des maladies rares grâce à la biologie des patients, a annoncé sa prochaine participation à la Jones Healthcare and Technology Innovation Conference.
Le PDG et CMO de l'entreprise, Dr. Dirk Thye, fera une présentation le mercredi 9 avril 2025. Les investisseurs et les parties intéressées peuvent accéder à une rediffusion de la présentation via la section Événements du site Web des Relations Investisseurs de Quince à l'adresse ir.quincetx.com.
Quince Therapeutics (Nasdaq: QNCX), ein biotechnologisches Unternehmen in der späten Entwicklungsphase, das sich auf die Behandlung seltener Krankheiten durch die Biologie der Patienten konzentriert, hat seine bevorstehende Teilnahme an der Jones Healthcare and Technology Innovation Conference bekannt gegeben.
Der CEO und CMO des Unternehmens, Dr. Dirk Thye, wird am Mittwoch, den 9. April 2025 eine Präsentation halten. Investoren und Interessierte können über den Bereich Veranstaltungen auf der Investor-Relations-Website von Quince unter ir.quincetx.com auf eine Wiederholung der Präsentation zugreifen.
- None.
- None.
A replay of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com.
About Quince Therapeutics
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403414477/en/
Media & Investor Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com
Source: Quince Therapeutics, Inc.
FAQ
When is Quince Therapeutics (QNCX) presenting at the Jones Healthcare Conference?
Where can investors watch the replay of QNCX's Jones Conference presentation?
What is Quince Therapeutics' (QNCX) current business focus?
Who will represent QNCX at the Jones Healthcare Conference?
